Suchergebnisse - "Schmid, Peter"

PubPharm (20)

1

TROPION-Breast02 : Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer

enthalten in: Future oncology (London, England) | 2023

von Dent, R. | Cescon, D. | Bachelot, T. | +9

2

Prognostic and predictive impact of gene expression in node-positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy

enthalten in: Molecular oncology | 2023

von Reinisch, M. | Bruzas, S. | Gluz, O. | +12

3

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer : A Detailed Safety Analysis of the Randomized PARSIFAL Trial

enthalten in: The oncologist | 2023

von Di Cosimo, S. | Pérez-García, J. | Bellet, M. | +20

4

Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Rugo, H. | Bardia, A. | Marmé, F. | +13

CommentIn: J Clin Oncol. 2023 Feb 1;41(4):732-735. - PMID 36446052

5

ASTEFANIA : adjuvant ado-trastuzumab emtansine and atezolizumab for high-risk, HER2-positive breast cancer

enthalten in: Future oncology (London, England) | 2022

von Hurvitz, S. | Bachelot, T. | Bianchini, G. | +13

6

Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer

enthalten in: The New England journal of medicine | 2022

von Modi, S. | Jacot, W. | Yamashita, T. | +136

CommentIn: Nat Rev Clin Oncol. 2022 Aug;19(8):493. - PMID 35778612

7

Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptor-Positive, ERBB2-Negative Advanced Breast Cancer : A Randomized Clinical Trial

enthalten in: JAMA oncology | 2021

von Llombart-Cussac, A. | Pérez-García, J. | Bellet, M. | +52

ErratumIn: JAMA Oncol. 2021 Nov 1;7(11):1729. - PMID 34792545

8

Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain) : a multicentre, randomised, open-label, non-comparative, phase 2 trial

enthalten in: The Lancet. Oncology | 2021

von Pérez-García, J. | Gebhart, G. | Ruiz Borrego, M. | +20

CommentIn: Future Oncol. 2022 Oct;18(33):3677-3688. - PMID 36300423

9

Pembrolizumab plus eribulin in hormone-receptor-positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY) : An open-label, multicentre, single-arm, phase Ⅱ trial

enthalten in: European journal of cancer (Oxford, England : 1990) | 2021

von Pérez-García, J. | Llombart-Cussac, A. | G Cortés, M. | +16

10

A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

enthalten in: Breast cancer research : BCR | 2021

von Schmid, P. | Sablin, M. | Bergh, J. | +17